Eisai Obtains Japanese Approval For Breast Cancer Drug Halaven
This article was originally published in PharmAsia News
Executive Summary
Eisai Co. Ltd. announced April 22 that it received approval to manufacture and market Halaven (eribulin) for the treatment of patients with inoperable and relapsed cancer in Japan